| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | -2,1 M € | +42.3% | -3,6 M € | -15.3% | -3,1 M € | -18.6% | -2,6 M € | -61.4% | -1,6 M € | +29.6% | -2,3 M € | |
| EBITDA | -2,8 M € | +38.1% | -4,5 M € | -7.8% | -4,2 M € | -18.5% | -3,5 M € | -65.8% | -2,1 M € | +12.5% | -2,4 M € | |
| Operating profit | -3,0 M € | +38.2% | -4,8 M € | -6.6% | -4,5 M € | -18.6% | -3,8 M € | -62.1% | -2,3 M € | +10.8% | -2,6 M € | |
| Profit/loss | -3,2 M € | +31.7% | -4,7 M € | -9.8% | -4,3 M € | -17.0% | -3,7 M € | -62.5% | -2,3 M € | +12.3% | -2,6 M € | |
| Equity | -5,0 M € | -181.3% | -1,8 M € | -160.5% | 2,9 M € | -59.4% | 7,2 M € | +84.6% | 3,9 M € | +79.2% | 2,2 M € | |
| Total assets | 3,0 M € | -9.5% | 3,3 M € | -11.9% | 3,7 M € | -55.1% | 8,3 M € | +54.1% | 5,4 M € | +103.8% | 2,6 M € | |
| Cash | 1,5 M € | -20.5% | 1,9 M € | -16.9% | 2,2 M € | -65.9% | 6,6 M € | +81.1% | 3,6 M € | +116.1% | 1,7 M € | |
| Debts | 7,3 M € | +50.2% | 4,9 M € | +538.2% | 766,3 k € | -9.1% | 843,0 k € | -0.7% | 848,6 k € | +88.9% | 449,3 k € | |
| Staff | 8,2 | 9,6 | 10,6 | 10,2 | 6,8 | 3,8 | ||||||
Private limited company · Leuven · incorporated on 24/07/2019 · 8,2 ETP
Private limited company loss-making in the latest fiscal year. Cash position declining (-20.5%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Montis Biosciences is a Private limited company incorporated in 2019. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Leuven. It employs on average 8,2 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette